Response Genetics (RGDX -2.7%) says it's reached its second milestone payment hurdle in...

|About: Response Genetics, Inc. (RGDX)|By:, SA News Editor

Response Genetics (RGDX -2.7%) says it's reached its second milestone payment hurdle in conjunction with a licensing agreement with GlaxoSmithKline (GSK) signed in 2010 to develop its BRAF-Inhibitor Tafinlar. Under the terms of the agreement, GSK gained certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise which received premarket approval from the FDA in May.